

A trial to determine if withholding anticoagulation is not worse than standard anticoagulation therapy in the treatment of blood clots in the lungs

Submission date 24/09/2020	Recruitment status Stopped	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 23/10/2020	Overall study status Stopped	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 28/02/2025	Condition category Circulatory System	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Pulmonary embolism (PE) is a condition where blood clots cause a blockage of the blood vessels in the lungs. PEs are often caused by blood clots in the legs (deep vein thrombosis [DVT]) breaking off and travelling to the lungs. The symptoms of a PE depend on the size and location of the blood clot and can include breathlessness and chest discomfort. The standard treatment for PE includes anticoagulant drugs commonly referred to as “blood thinners”. Anticoagulants include a drug called warfarin, direct oral anticoagulant (DOACs) tablets, or a type of drug called “low molecular weight heparin” that is injected under the skin. These drugs stop new clots from forming while the body breaks down clots that may have already formed. A PE is diagnosed by a scan of the lungs, which is most commonly a computed tomography pulmonary angiogram (CTPA). This gives doctors images of the pulmonary arteries, a small PE in these blood vessels is called a “subsegmental pulmonary embolism” (SSPE).

As the CTPA scanning technology for PE has become more sensitive, smaller clots are being diagnosed. The CTPA scans are now able to detect smaller blood clots in blood vessels of the lungs; these clots are only a few millimetres in size and are the subsegmental pulmonary embolisms (SSPE).

The current standard treatment for pulmonary embolism is anticoagulant drugs. The aim is to reduce future blood clots (PEs and DVTs). It is unclear if the smaller clots, the SSPEs, require treatment with anticoagulation as these smaller PEs may be broken down by the body itself without the need for any treatment. Patients with SSPE who are treated with anticoagulation could be more at harm due to the risk of bleeding than they are helped by preventing future blood clots. This study will compare the outcomes among people with SSPE who have no anticoagulation treatment with those that are anticoagulated. The results of this will help us find out which is the best treatment plan for patients with SSPE.

Who can participate?

Patients aged 18 and older with a subsegmental pulmonary embolism

What does the study involve?

Participants are randomly allocated to either continue with standard anticoagulation or to have no anticoagulation treatment at all and are assessed after 12, 24 and 52 weeks.

What are the possible benefits and risks of participating?

Although participants may not receive any individual benefit from taking part in the study, the results may help to improve the treatment of patients with SSPE in the future. If the participant is allocated to have anti-coagulation treatment then the potential risks are the same as usual care which will have already been discussed with the participant. The participant may experience bleeding from the anticoagulants, which can be minor like a small nose bleed or sometimes more severe (where the participant might need to come to hospital to have a blood transfusion). If the participant is allocated to the no treatment group then they are less likely to have either bleeding as they will not be on anticoagulants, but they may get another blood clot in the lungs (PE) or legs (DVT). The participant will be given a patient card that explains the symptoms to look out for which should prompt them to seek healthcare in case they have had another PE or DVT.

Where is the study run from?

University of Birmingham (UK)

When is the study starting and how long is it expected to run for?

October 2019 to March 2024

Who is funding the study?

National Institute for Health Research (NIHR) (UK)

Who is the main contact?

Pooja Gaddu

stopape@trials.bham.ac.uk

Contact information

Type(s)

Scientific

Contact name

Miss Pooja Gaddu

Contact details

Birmingham Clinical Trials Unit

University of Birmingham

Edgbaston

Birmingham

United Kingdom

B15 2TT

+44 (0)121 415 9120

stopape@trials.bham.ac.uk

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

Integrated Research Application System (IRAS)

280586

ClinicalTrials.gov (NCT)

NCT04727437

Protocol serial number

CPMS 46105, IRAS 280586

Study information

Scientific Title

STOPping Anticoagulation for isolated or incidental subsegmental Pulmonary Embolism

Acronym

STOP-APE

Study objectives

To determine if withholding anticoagulation is non-inferior to standard anticoagulation therapy in the treatment of isolated subsegmental pulmonary embolism (ISSPE) for preventing recurrent venous thromboembolism (VTE), or death related VTE, or superior for clinically relevant bleeding over 3 months, compared with at least 3 months of full anticoagulation.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 30/09/2020, Wales REC 6 (c/o Public Health Wales, Building 1, Jobswell Road, St David's Park, SA31 3HB, UK; +44 (0)1267 61 1164; Wales.REC6@wales.nhs.uk), REC ref: 20/WA/0256

Study design

Randomized; Interventional; Design type: Treatment, Diagnosis, Drug, Management of Care

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Isolated or incidental subsegmental pulmonary embolism

Interventions

The design is a prospective randomised open blinded end point (PROBE) trial, with individual level randomisation. The researchers have used an open design because of the importance of understanding how the knowledge of a diagnosis of SSPE yet being sent home without anticoagulation affects health seeking behaviour. This would be the situation in real clinical practice, were the results of the trial to support no anticoagulation. If the researchers had opted

for a placebo-controlled trial they would not be able to predict the impact of the management strategy in routine practice. An internal pilot (first 12 months of recruitment) will inform progression criteria to the main trial and a nested study of diagnostic accuracy will ensure safety for participants.

Process evaluation: The researchers will focus on acceptability and the potential consequences of a no treatment approach, through conducting interviews with a range of patients (n=30) and healthcare professionals (HCP; n=30). The topic guide will be developed drawing on existing literature on reporting of, attitudes to, and outcomes from incidental diagnoses. The researchers will explore attitudes and practical issues surrounding tolerance of risk by patients and HCPs. If having a PE and knowingly not being treated changes how one responds to transient symptoms (e.g. leg or chest pain) then a potential outcome may be excess scans and emergency presentations in the untreated group. Distress at receiving a diagnosis of VTE, particularly as an incidental finding and the harm of repeated diagnostic imaging in this context will therefore be important to assess. Interviews will be audio recorded and transcribed verbatim, prior to qualitative analysis using the framework method. If patient/health care professional consents to this they will be interviewed by a researcher at a place that is convenient for them, either face-to-face in their own home or a hospital site, or by telephone /video call. The interview will take around one hour and will be tape recorded.

The potential for an increase in emergency presentations and diagnostic tests, may mean that there are additional NHS costs of no treatment, in spite of the cost savings in medication. Therefore, the researchers will undertake an economic evaluation to assess the cost-effectiveness of no treatment versus full dose anticoagulation in patients with isolated SSPE.

Nested CTPA study: A nested study of all CTPAs will be performed, comparing the SSPE diagnosis made by the acute reporting radiologists with specialist thoracic radiologists. This will allow us to determine safety in the pilot study (patients with larger than subsegmental clot are rapidly identified), appropriate powering and sample size (e.g. patients with breathing artefact may be recruited instead of true SSPE) and develop guidance for SSPE diagnosis in routine clinical practice.

Estimated total trial duration is 54 months comprising of setup (6 months), recruitment (32 months), follow-up (12 months) and analysis/write up (4 months).

Patients will be approached by a member of the local research team who will introduce the trial to them and provide the patient information sheet for their consideration. Patients will then be asked to sign an informed consent form to consent to the screening procedures and for their CTPA imaging to be transferred for central radiology review.

Screening:

Patients who also have DVT as well as a SSPE cannot take part in the trial. If they have already had a computed tomography (CT) scan or magnetic resonance imaging (MRI) to confirm DVT status they will need to have a ultrasound scan of their legs to look for DVT.

Pregnant patients cannot participate in the trial therefore women likely to become pregnant will be required to take a pregnancy test.

As part of the eligibility assessment patients will be required to have a physical examination, they will have their medical history, vital signs and current medication assessed.

Patients will be asked to complete the EQ-5D-5L health questionnaire at baseline.

If following screening the patient is found to be eligible they will be asked if they are willing to be randomised and sign an additional informed consent form.

The patient will be randomized 1:1 to either anti-coagulation treatment for at least three months or no anti-coagulation treatment.

Follow up:

Primary outcome analysis at 3 months with patient follow up assessments via telephone at 30 days, 3 and 6 months post randomization.

At the 4 week assessment patients will be contacted to provide data on recurrent VTE.

At the 3 and 6 months assessment patients will be contacted and asked to complete the EQ-5D-5L health questionnaire. They will also be asked about symptoms relating to VTE, bleeding events, hospitalisations and bed days for VTE or bleeding, VTE recurrence, EQ-5D-5L, unscheduled visits to primary/secondary care for symptoms potentially related to VTE, whether anti-coagulation treatment has been stopped or started.

The researchers will use an efficient design for 12 month follow-up through targeted extractions from NHS Digital and consent to access medical records. These extractions will include VTE recurrence at 12 months, rate of new diagnosis of pulmonary hypertension or right ventricular dysfunction (coded in hospital or HES record), death due to PE/VTE.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

-

Primary outcome(s)

Recurrent venous thromboembolism (VTE), death-related VTE, or clinically relevant bleeding, assessed using case report forms at the 12 and 24 week follow up timepoints

Key secondary outcome(s)

1. Reduction in recurrent VTE and bleedings event assessed using case report forms at the 12, 24 and 52-week timepoints
2. Reclassification rate of SSPE diagnoses made by acute reporting radiologists when reviewed by thoracic radiologists, recorded on a case report form at registration/randomisation
3. Healthcare resource use: hospitalisations, bed days, unscheduled primary and secondary care visits for recurrent VTE, clinically relevant bleeding or potentially related symptoms, measured using case report forms at the 12, 24 and 52-week timepoints
4. Healthcare costs assessed using case report forms at the 12, 24 and 52-week timepoints
5. Health-related quality of life measured using the EQ-5D-5L questionnaire at baseline, 12 and 24 weeks
6. Cost-utility (cost per QALY) measured using a case report form at 24 weeks and cost-effectiveness (cost per VTE avoided) measured at 52 weeks

5. Acceptability to patients and clinicians and health-seeking behaviours and health utilisation of a no anticoagulation treatment strategy for isolated SSPE, assessed through audio-recorded interviews which can occur at any point throughout the trial

Completion date

31/03/2024

Eligibility

Key inclusion criteria

1. Age ≥ 18 years
2. SSPE diagnosed by the radiologist at the trial site by CTPA or CT thorax with IV contrast
3. No evidence of proximal deep vein thrombosis on doppler ultrasonography or CT/MR venography
4. Heart rate < 110 bpm
5. Systolic blood pressure ≥ 100 mmHg
6. Oxygen saturation $\geq 90\%$
7. Written signed informed consent to the trial

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. Indication for hospital admission
2. > 7 days empirical anticoagulation treatment immediately prior to randomisation
3. < 28 days since first symptoms of proven or clinically suspected COVID-19
4. Known stage 5 chronic kidney disease
5. Patients with active cancer defined as cancer diagnosed within the past 6 months, cancer for which anticancer treatment was being given at the time of enrolment or during 6 months before randomisation, or recurrent locally advanced or metastatic cancer
6. Patients with previous unprovoked PE, thrombophilia or requiring long term anticoagulation for another reason
7. Patients with a DVT / thrombus of an unusual site (e.g. upper limbs, associated with a line) that requires anticoagulation
8. Patients with active bleeding
9. Any condition which, in the opinion of the investigator, makes the participant unsuitable for trial entry due to prognosis/terminal illness with a projected survival of less than 3 months
10. Pregnancy confirmed by positive pregnancy test or post-partum period or actively trying to

conceive

11. Inability to comply with the trial schedule and follow-up

12. Participation in a CTIMP study

Date of first enrolment

08/04/2021

Date of final enrolment

30/06/2023

Locations

Countries of recruitment

United Kingdom

England

Scotland

Wales

Study participating centre

Airedale NHS Foundation Trust

Airedale General Hospital

Skipton Road

Steeton

United Kingdom

BD20 6TD

Study participating centre

Calderdale and Huddersfield NHS Foundation Trust

Trust Headquarters

Acre Street

Lindley

Huddersfield

United Kingdom

HD3 3EA

Study participating centre

Cardiff & Vale University LHB

Woodland House

Maes-Y-Coed Road

Cardiff

United Kingdom

CF14 4HH

Study participating centre
Chelsea and Westminster Hospital NHS Foundation Trust
Chelsea & Westminster Hospital
369 Fulham Road
London
United Kingdom
SW10 9NH

Study participating centre
The Christie NHS Foundation Trust
550 Wilmslow Road
Withington
Manchester
United Kingdom
M20 4BX

Study participating centre
NHS Forth Valley
33 Spittal Street
Stirling
United Kingdom
FK8 1DX

Study participating centre
Frimley Health NHS Foundation Trust
Portsmouth Road
Frimley
Camberley
United Kingdom
GU16 7UJ

Study participating centre
The Royal Wolverhampton NHS Trust
New Cross Hospital
Wolverhampton Road
Heath Town
Wolverhampton
United Kingdom
WV10 0QP

Study participating centre

NHS Lothian

Waverley Gate
2-4 Waterloo Place
Edinburgh
United Kingdom
EH1 3EG

Study participating centre

North Bristol NHS Trust

Southmead Hospital
Southmead Road
Westbury-On-Trym
Bristol
United Kingdom
BS10 5N

Study participating centre

North Tees and Hartlepool NHS Foundation Trust

University Hospital of Hartlepool
Holdforth Road
Hartlepool
United Kingdom
TS24 9AH

Study participating centre

Northumbria Healthcare NHS Foundation Trust

North Tyneside General Hospital
Rake Lane
North Shields
United Kingdom
NE29 8NH

Study participating centre

Nottingham University Hospitals NHS Trust

Trust Headquarters
Queens Medical Centre
Derby Road
Nottingham
United Kingdom
NG7 2UH

Study participating centre
NHS Greater Glasgow and Clyde
J B Russell House
Gartnavel Royal Hospital
1055 Great Western Road
Glasgow
United Kingdom
G12 0XH

Study participating centre
Royal Berkshire NHS Foundation Trust
Royal Berkshire Hospital
London Road
Reading
United Kingdom
RG1 5AN

Study participating centre
The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust
Royal Bournemouth General Hospital
Castle Lane East
Bournemouth
United Kingdom
BH7 7DW

Study participating centre
Pennine Acute Hospitals NHS Trust
Trust Headquarters
North Manchester General Hospital
Delaunays Road
Crumpsall
Manchester
United Kingdom
M8 5RB

Study participating centre
Royal United Hospitals Bath NHS Foundation Trust
Combe Park
Bath
United Kingdom
BA1 3 NG

Study participating centre
Salford Royal NHS Foundation Trust
Salford Royal
Stott Lane
Salford
United Kingdom
M6 8HD

Study participating centre
Sandwell and West Birmingham Hospitals NHS Trust
City Hospital
Dudley Road
Birmingham
United Kingdom
B18 7QH

Study participating centre
Leeds Teaching Hospitals NHS Trust
St. James's University Hospital
Beckett Street
Leeds
United Kingdom
LS9 7TF

Study participating centre
Stockport NHS Foundation Trust
Stepping Hill Hospital
Poplar Grove
Stockport
United Kingdom
SK2 7JE

Study participating centre
University Hospitals Birmingham NHS Foundation Trust
Queen Elizabeth Hospital
Mindelsohn Way
Edgbaston
Birmingham
United Kingdom
B15 2GW

Study participating centre
University Hospitals of North Midlands NHS Trust
Newcastle Road
Stoke-On-Trent
United Kingdom
ST4 6QG

Study participating centre
University Hospital Southampton NHS Foundation Trust
Southampton General Hospital
Tremona Road
Southampton
United Kingdom
SO16 6YD

Study participating centre
Whittington Health NHS Trust
The Whittington Hospital
Magdala Avenue
London
United Kingdom
N19 5NF

Study participating centre
Worcestershire Acute Hospitals NHS Trust
Worcestershire Royal Hospital
Charles Hastings Way
Worcester
United Kingdom
WR5 1DD

Study participating centre
Manchester University NHS Foundation Trust
Cobbett House
Oxford Road
Manchester
United Kingdom
M13 9WL

Study participating centre
York Teaching Hospital NHS Foundation Trust
York Hospital
Wigginton Road
York
United Kingdom
YO31 8HE

Study participating centre
University Hospitals of Morecambe Bay NHS Foundation Trust
Westmorland General Hospital
Burton Road
Kendal
United Kingdom
LA9 7RG

Study participating centre
Cambridge University Hospitals NHS Foundation Trust
Cambridge Biomedical Campus
Hills Road
Cambridge
United Kingdom
CB2 0QQ

Study participating centre
County Durham and Darlington NHS Foundation Trust
Darlington Memorial Hospital
Hollyhurst Road
Darlington
United Kingdom
DL3 6HX

Study participating centre
The Newcastle upon Tyne Hospitals NHS Foundation Trust
Freeman Hospital
Freeman Road
High Heaton
Newcastle upon Tyne
United Kingdom
NE7 7DN

Study participating centre
Sheffield Teaching Hospitals NHS Foundation Trust
Northern General Hospital
Herries Road
Sheffield
United Kingdom
S5 7AU

Study participating centre
Milton Keynes University Hospital NHS Foundation Trust
Standing Way
Eaglestone
Milton Keynes
United Kingdom
MK6 5LD

Sponsor information

Organisation
University of Birmingham

ROR
<https://ror.org/03angcq70>

Funder(s)

Funder type
Government

Funder Name
NIHR Evaluation, Trials and Studies Co-ordinating Centre (NETSCC); Grant Codes: NIHR128073

Results and Publications

Individual participant data (IPD) sharing plan

The data sharing plans for the current study are unknown and will be made available at a later date

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
HRA research summary			28/06/2023	No	No
Other publications	Process evaluation	26/02/2025	28/02/2025	Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Study website	Study website	11/11/2025	11/11/2025	No	Yes